(Q45397586)

14 December 2017

title

Atherosclerosis drug development in jeopardy: the need for predictive biomarkers of treatment response (English)

1 reference

14 December 2017

1 reference

1 reference

David A Fryburg

1

1 reference

14 December 2017

Maria T Vassileva

series ordinal

2

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Science Translational Medicine

14 December 2017

published in

1 reference

14 December 2017

volume

3

1 reference

14 December 2017

issue

72

1 reference

14 December 2017

page(s)

72cm6

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Conference report: Bosnia and Herzegovina. The Fourth International Congress of Cardiologists and Angiologists, Mostar; Bosnia and Herzegovina, May 17 to 19, 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Prevalence of conventional risk factors in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Predicting the risk of coronary heart disease I. The use of conventional risk markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

The forgotten majority: unfinished business in cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Multimodality cardiovascular molecular imaging, part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Form to function: current and future roles for atherosclerosis imaging in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Multimodality cardiovascular molecular imaging, Part II

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Imaging of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Non-invasive vascular function tests: their pathophysiological background and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Multiple biomarkers for the prediction of first major cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Multi-organ whole-genome measurements and reverse engineering to uncover gene networks underlying complex traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

The use of network analyses for elucidating mechanisms in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002029

10.1126/SCITRANSLMED.3002029

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference